Drug Profile
Peginterferon lambda-1a biosimilar - Nanogen Biopharmaceutical
Alternative Names: Peglamda; Pegylated interferon lambda 1Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Nanogen Biopharmaceutical Co
- Class Antivirals; Interferons; Interleukins
- Mechanism of Action Immunostimulants; Interleukin 29 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hepatitis B; Hepatitis C
Most Recent Events
- 28 May 2019 No recent reports of development identified for phase-I development in Hepatitis-C(Treatment-naive, In volunteers) in Vietnam (SC, Injection)
- 13 Dec 2016 Peginterferon lambda-1a biosimilar is still in phase I development for Hepatitis C in Vietnam
- 01 Jul 2016 Nanogen Biopharmaceuticals completes a phase I trial in Hepatitis C (In volunteers and Treatment-naive patients) in Vietnam (SC)